ReviewEpigenomics2026
Interplay of the 3D genome and epigenome in androgen-driven prostate cancer.
Review in Epigenomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding of the therapeutic landscape for androgen-driven prostate cancer has undergone significant evolution, yet treatment resistance remains an ongoing challenge. The androgen receptor (AR) plays a central role in androgen-dependent prostate tumor growth, and therapeutic agents targeting AR represent the main treatment modality for prostate cancer. AR transcriptional activity is tightly regulated by coregulatory transcription factors and their DNA binding and activity. However, the precise interactions between AR and three-dimensional (3D) chromatin structure and its dynamic remodeling represent a critical yet underexploited therapeutic frontier. Here, we present a perspective on how the spatial architecture of the epigenome, including 3D chromatin structure and dynamics, orchestrates dysregulation of transcription factor networks that help to drive disease progression in androgen-driven prostate cancer. We argue that successful therapeutic intervention requires moving beyond linear epigenetic marks toward a three-dimensional understanding of the epigenetic landscape. Such a shift is essential to capture the complex enhancer-promoter communications and chromatin state transitions that define the disease. Drawing on recent advances in prostate cancer biology and technological developments, we propose a unique integrated framework centered on patient-specific 3D epigenomic vulnerabilities for next-generation epigenetic therapies designed to disrupt oncogenic transcriptional programs by specifically targeting chromatin topology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.